CityMD Agrees to $12 Million to Pay Department of Justice Over Alleged Covid-19 Payments Violation — Update
By Sabela Ojea
CityMD has agreed to pay more than $12 million to the Department of Justice for allegedly submitting false claims for payment for Covid-19 testing to the Health Resources and Services Administration governmental program for uninsured patients.
The urgent-care chain's settlement resolves allegations related to the violation of the False Claims Act, the Department of Justice's Office of Public Affairs said Friday. The act encourages people with knowledge of suspected false claims to sue on the government's behalf.
"The recent settlement is neither a finding of liability nor an admission of wrongdoing, and CityMD denies the allegations," a company spokesperson said. "However, we settled this matter to avoid the cost and burden of prolonged litigation."
CityMD is owned by Walgreens Boots Alliance after the pharmacy operator acquired Summit Health in a late 2022 transaction worth roughly $9 billion, including debt.
From Feb. 4, 2020, to April 5, 2022, CityMD allegedly knowingly submitted payment for Covid-19 testing to the Uninsured Program for individuals who had health insurance coverage when CityMD administered those tests, the DOJ said.
CityMD cooperated with the investigation and voluntarily contracted a third party to assist in determining the amount of the losses the U.S. contends were caused by claims submitted to the Uninsured Program for patients who had health insurance, the DOJ said.
"We remain proud that we were available to our patients at all times throughout the pandemic, and we look forward to continuing to serve them," the company spokesperson said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 07, 2024 19:06 ET (23:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks